Methicillin-resistant Staphylococcus aureus skin and soft tissue infections in young people in custody in New South Wales

Journal of Paediatrics and Child Health
Leigh HaysomKimberley Sneddon

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs) are problematic for incarcerated adolescents but have not been previously researched. This was a 2-year prospective study of all New South Wales Juvenile Custodial Centres involving incarcerated youth aged 12-20 years. The main outcomes measured were MRSA SSTIs, MRSA molecular subtypes and associations with MRSA infection. Variables included age, gender, SSTI site and type, Indigenous status, incarceration time, lifetime incarcerations, intravenous drug use, overweight/obesity, recent antibiotic use and health centre presentations. From February 2013 to January 2015, there were 77 SSTIs (92.2% male, 59.2% Indigenous, mean age 16.9 years). The majority (77.9%) were collections, mostly on the lower limb (44.2%), and 33 (42.9%) isolates were MRSA; 94% were Panton-Valentine leukocidin positive. This represents 11 SSTIs per 1000 custodial admissions, and 4.7 MRSA SSTIs per 1000 custodial admissions. Independent associations with MRSA SSTI (vs. non-MRSA SSTI) were Indigenous status (adjusted odds ratio (AOR) 5.92, P < 0.001), presenting with a collection (AOR 18.29, P < 0.001) and recent antibiotic use (AOR 3.62, P < 0.05). Incarcerated Austral...Continue Reading

References

Jun 13, 1998·Burns : Journal of the International Society for Burn Injuries·N Cook
Jun 11, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Susan H WoottonMatthew J Kuehnert
Jun 18, 2004·The Medical Journal of Australia·Sebastiaan J M van Hal, Jeffrey J Post
Apr 28, 2005·The Lancet Infectious Diseases·Nicola ZetolaWilliam R Bishai
Jun 1, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Y PelegF Huygens
May 9, 2007·The Medical Journal of Australia·David C RissonGraeme R Nimmo
Mar 15, 2008·The Journal of Antimicrobial Chemotherapy·Dilip NathwaniUNKNOWN British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections
Mar 18, 2008·International Journal of Antimicrobial Agents·Graeme R Nimmo, Geoffrey W Coombs
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Steven Y C TongBart J Currie
Mar 9, 2010·Lancet·Frank R DeLeoHenry F Chambers
Nov 3, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cynthia L MareeLoren G Miller
Jun 3, 2011·New South Wales Public Health Bulletin·Wendy L WatsonRebecca J Mitchell
Aug 4, 2011·Archives of Pediatrics & Adolescent Medicine·Verena Schneider-LindnerSamy Suissa
Apr 18, 2018·Journal of Correctional Health Care : the Official Journal of the National Commission on Correctional Health Care·Leigh HaysomStephen Hampton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.